India Intravenous Anesthetic Market

India Intravenous Anesthetic Market, by Type (Barbiturates, Ketamine, Benzodiazepines, Propofol, and Others) and by End User (Hospitals, Clinics, and Others)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Intravenous anesthetics are medications that are administered through a vein to induce and maintain anesthesia during surgical procedures. They work by depressing the central nervous system and causing loss of consciousness, loss of sensation, and muscle relaxation. Some common intravenous anesthetics include propofol, etomidate, ketamine, and barbiturates. These medications should only be administered by trained medical professionals in a controlled environment to ensure patient safety. Intravenous anesthetics are a group of fast-acting compounds that are used to induce a state of impaired awareness or complete sedation during surgical procedures. Intravenous anesthetics work by depressing the central nervous system, leading to loss of consciousness, loss of sensation, and muscle relaxation. The importance of accurately controlling the dose-response relation for intravenous anesthetics is directly related to optimizing the efficacy and quality of anesthesia while minimizing adverse drug effects. Intravenous nonopioid anesthetics have an important role in modern anesthesia practice and are widely used to facilitate a rapid induction of general anesthesia and provide sedation during monitored anesthesia care (MAC) and for patients in intensive care settings.

Market Dynamics

Increase in geriatric population with chronic diseases is anticipated to drive the growth of market in India. For instance, according to Longitudinal Ageing Study in India (LASI) released by the Union Ministry of Family and Health Welfare on January 6 2020 in India two in every three senior citizens suffer from some chronic disease. The Chronic health conditions are more prevalent in people aged 75 and up, with cardiovascular disease (CVD) and hypertension dominating.

Key features of the study:

• This report provides an in-depth analysis of the India intravenous anesthetic market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the India intravenous anesthetic market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AstraZeneca, Plc. Fresenius Kabi, AbbVie Inc., Baxter International Inc., Braun Melsungen AG, Maruishi Pharmaceutical. Co., Ltd., Piramal Pharma Ltd., Hikma Pharmaceuticals, Inc., and Viatris Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• India intravenous anesthetic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the India intravenous anesthetic market.

Detailed Segmentation:

• India Intravenous Anesthetic Market, By Type:
• Barbiturates
• Ketamine
• Benzodiazepines
• Propofol
• Others
• India Intravenous Anesthetic Market, By End User:
• Hospitals
• Clinics
• Others
• Company Profiles
• AstraZeneca, Plc.
• Fresenius Kabi
• AbbVie Inc.
• Baxter International Inc.
• Braun Melsungen AG
• Maruishi Pharmaceutical. Co., Ltd.
• Piramal Pharma Ltd.
• Hikma Pharmaceuticals, Inc.
• Viatris Inc.